Navigation Links
Aethlon Medical to Present at the Singular Research Fifth Annual 'Best of the Uncovereds Conference'
Date:11/3/2010

SAN DIEGO, Nov. 3, 2010 /PRNewswire/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that it will present tomorrow at the at the Singular Research Fifth Annual "Best of the Uncovereds" Conference in Los Angeles.

(Photo:  http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

(Photo:  http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

Jim Joyce, Aethlon's Chairman & CEO, will present at 11:20 a.m. and during the remainder of the day, Mr. Joyce will meet with investors during a series of one-on-one breakout meetings at the conference.  The conference (http://www.singularresearch.com/botu2010.htm) is being held at the Luxe Sunset Boulevard Hotel in Los Angeles.  

Aethlon also disclosed that on Saturday, November 6, 2010, Jim Frakes, Aethlon's CFO, will present at RedChip's Small-Cap Investor Conference at Financial Fest 2010 in Phoenix, Arizona. The conference (http://www.redchip.com/visibility/conferencePages/Phoenix2010/conferenceMain.asp)  will be held at the Phoenix Convention Center.

About Aethlon MedicalAt Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:

  1. Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
  2. Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.  
  3. Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  4. Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.Contacts:James A. JoyceChairman, CEO858.459.7800 x301jj@aethlonmedical.comJohn P. SalvadorDirector, Communications & Investor Relations858.459.7800 x307jps@aethlonmedical.comJon CunninghamRedChip Companies, Inc.800.733.2447 x107jon@redchip.com
'/>"/>

SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Names Rod Kenley President
2. Aethlon Medical Announces Appointment of Rod Kenley to Its Board of Directors
3. Aethlon Medical Engages Fabiani & Company to Advance U.S. Government Partnerships
4. Aethlon Medical Reestablishes Biodefense Programs
5. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
6. Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program
7. Aethlon Medical Announces Expansion of Hepatitis C Virus (HCV) Treatment Programs
8. Aethlon Medical Discloses Live Webcast of Todays BIOCOM Presentation
9. Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus
10. Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference
11. Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
(Date:5/4/2017)... 2017 Clarius Mobile Health, a digital ... scanners this week at the American Congress of ... San Diego, CA from ... the perfect tool for clinicians to easily confirm ... evaluate pregnancy-related complications like ectopic pregnancy and placenta ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
Breaking Medicine Technology:
(Date:5/26/2017)... , ... May 26, 2017 , ... Dr. Alex Rabinovich, ... to announce a new, informational blog post on insurance options. If a Bay Area ... plans may help save time and money. Visiting an in-network provider for a second ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Cactus Jack: Against All Odds”: the story of ... “Cactus Jack: Against All Odds” is the creation of published author, Walter Hubbard, a ... to Jack Carlisle’s third child Jane. Walter. Walter and Jane have three adult ...
(Date:5/24/2017)... ... May 24, 2017 , ... Altec Products, Inc., ... nVerge 2017 – a one-day technology conference in San Diego, CA. , At ... allows users to fully utilize and enhance their Sage ERP solutions by providing improved ...
(Date:5/24/2017)... Washington, DC (PRWEB) , ... May 24, 2017 ... ... The Center for Global Policy Solutions is vehemently opposed to Donald Trump’s budget, ... old formula for despair that inspires fear, demonizes the poor, marginalizes underserved populations, ...
(Date:5/24/2017)... ... May 24, 2017 , ... Accordant Technology, ... solutions portfolio. ExtraHop delivers an analytics-first approach, layered with machine learning, that provides ... the datacenter to the cloud to the edge. Through the new partnership, customers ...
Breaking Medicine News(10 mins):